Roche to Invest $550 Mn in Indianapolis Diagnostics Manufacturing Expansion

According to the company's press release, the Indiana site will become a key manufacturer of Roche’s continuous glucose monitoring tools.

Biotechnology and pharmaceutical firm Roche announced plans to invest up to $550 million over the next five years to expand its diagnostics manufacturing facility in Indianapolis.

According to the company's press release, the Indiana site will become a key manufacturer of Roche’s continuous glucose monitoring tools.

The facility currently produces 5.2 billion Accu-Chek diabetes strips annually, which are distributed to 53 countries. It is one of two global distribution sites serving the U.S. market.

“The expansion will support increased demand and strengthen our diagnostics manufacturing capabilities,” the company stated.

In addition to manufacturing, the Indianapolis site houses Roche’s U.S.-based research and development, laboratory operations, distribution, IT, and administrative functions.

Recently, Roche announced a broader commitment to invest USD 50 billion in the United States over the next five years. The plan aims to expand the company’s pharmaceutical and diagnostics infrastructure and enhance manufacturing and research operations across multiple U.S. states.

In a separate update, the Indian Institute of Technology Madras Centre for Responsible AI (CeRAI) has partnered with Roche Diagnostics International Ltd, Switzerland. Under a Memorandum of Understanding (MoU), Roche has joined CeRAI as a Gold Consortium Member.

The collaboration will focus on ethical and responsible AI frameworks for in-vitro diagnostics (IVD) and digital health solutions.